Pfizer CEO Albert Bourla about the ADC technology for treating cancer

"The ADC, I think, what mRNA technology was for COVID vaccines, so very fast development of very effective vaccines, could be for cancer. The way that it works is that usually with cancer, we use, let's say, poisons, chemotherapy, right? So that is killing the cancer cells, but at the same time, unfortunately, it's killing the healthy cells. That's why I have all these side effects with chemo.
The idea of the ADC is that we will send the chemo only to the cancer cells. So you take the drug, which is the chemo, or anything else. You take the antibody, which is like a GPS guided missile. You put the two together and you send through the antibody the drug where you want. If you change the antibody, you can go from lung cancer to brain cancer to kidney cancer to bone cancer. And if you change the drug you can have a nuclear warhead or a chemical warhead or a tactical weapon warhead based on what is the need. So it's a huge trust platform that I'm very, very optimistic that will deliver significant solutions."